IN THE CLAIMS

This listing of claims replaces all prior versions in this application.

Claims 1-22 (canceled)

23. (currently amended) A fusion protein characterized in that it ~~comprises~~ consists essentially of allergens Parj1 and Parj2 of the *Parietaria judaica* species, in that each of said allergens lacks three ~~one or more of the four~~ disulphide bridges present in wild type allergens, ~~at least one in the amino terminal region comprised between amino acid residues 1 and 30,~~ and in that each of said allergens maintains essentially the same length as wild type allergens; wherein said fusion protein ~~comprises~~ consists of the amino acid sequence SEQ ID NO: 4.

Claims 24-32 (canceled)

33. (withdrawn-currently amended) A method for using the fusion protein according to claim 23, the method comprising administration of said fusion protein to a patient.

34. (withdrawn-currently amended) A method according to claim 33 for specific immunotherapy (SIT) treatment of allergies, the method comprising administration to a patient of said fusion protein as a hypoallergenic immunologic agent in the specific immunotherapy (SIT) treatment of allergies.

35. (withdrawn-currently amended) A method according to claim 33 for treatment of rhinitis, conjunctivitis, urticaria, angioedema, eczema, dermatitides, asthma, or anaphylactic shock, the method comprising

administration to a patient of said fusion protein in treatment of rhinitis, conjunctivitis, urticaria, angioedema, eczema, dermatitides, asthma, or anaphylactic shock.

36. (withdrawn) A method for preparation of a DNA vaccine, the method comprising mixing DNA coding for the fusion protein according to claim 23 in a DNA vaccine.

37. (previously presented) A pharmaceutical composition comprising the fusion protein according to claim 23 and a pharmaceutically acceptable excipient.

38. (previously presented) The pharmaceutical composition according to claim 37 in the form of a solution, suspension, emulsion, cream, ointment or implant.

39. (previously presented) The pharmaceutical composition according to claim 37, for parenteral, subcutaneous, intramuscular, intravenous, topical, or oral administration or for subcutaneous implantation.

40. (withdrawn-currently amended) A method for preparation of the fusion protein according to claim 23, the method comprising mutating amino acid sequences of allergens Parj1 and Parj2 of the *Parietaria judaica* species and linking them directly or via a spacer for chemical synthesis or by expression, in the form of said fusion protein ~~comprising~~ consisting of the amino acid sequence SEQ ID NO: 4, in a genetically modified host cell.

41. (withdrawn) The method for preparation according to claim 40, further comprising transforming a host cell with an expression vector comprising

DNA coding for the amino acid sequence SEQ ID NO: 4.

Claims 42-43 (canceled)

44. (currently amended) A method for preparation of the pharmaceutical composition according to claim 37, the method comprising mixing said fusion protein in an immunologically active amount with a pharmaceutically acceptable excipient.

Claims 45-48 (canceled)

49. (withdrawn-currently amended) A method according to claim 33, wherein said fusion protein is prepared in the form of a solution, suspension, emulsion, cream, ointment or implant.

50. (withdrawn-currently amended) A method according to claim 33, wherein said fusion protein is parenterally, subcutaneously, intramuscularly or intravenously administered.

51. (withdrawn-currently amended) A method according to claim 33, wherein said fusion protein is topically administered.

52. (withdrawn-currently amended) A method according to claim 33, wherein said fusion protein is orally administered.

53. (withdrawn-currently amended) A method according to claim 33, wherein said fusion protein is administered by subcutaneous implantation.

54. (withdrawn-currently amended) A method for using the fusion protein according to claim 23, the method comprising administration of said fusion protein to a cell.